BioSpace News Archive

QCCA Network of 20 Oncology Practices to Integrate Population Health Analytics Solutions to Achieve Clinical and Financial Objectives Under Value-Based Care

Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group, has acquired New England Discovery Partners (NEDP), a Contract Research Organization (CRO) specializing in synthetic and medicinal chemistry.

Digestive health startup Vivante Health, creators of the GIThrive all-in-one digital health solution for gut health and disease, announced Jonathan Fox has joined the company’s Board of Advisors.

MarkLogic Corporation, the next-generation data platform provider for simplifying data integration, together with eyeforpharma, a hub for senior-level pharma executives, patient advocacy groups and other health experts, released a report of gathered insights from pharmaceutical leaders on how data challenges and data sharing will impact the future of patient care and healthcare costs.

ValGenesis Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that a global healthcare services and products company has gone live with ValGenesis’s 100% paperless VLMS to digitize and standardize corporate validation lifecycle processes across the organization.

Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals.

More than 500 children undergo heart transplants in the U.S. each year, joining the thousands of children already living with a new heart, and while medical advancements have improved over the years, many of these children and their families still face a lifetime of challenges.

Kenai Spine, a regional spine center based in Alaska, is bringing the most advanced spine surgery capabilities to opposite sides of the planet, from Alaska to Africa.

Emerging research begins to identify neighborhood characteristics that could impact the incidence of and vulnerability to chronic disease

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its abstract for the Phase III study of oral paclitaxel and encequidar (Oral Paclitaxel) in metastatic breast cancer has been selected for the press program of the 2019 San Antonio Breast Cancer Symposium (SABCS).